My watch list  

Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects Evotec is providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

Evotec's proprietary projects specialise in finding new treatments for diseases of the Central Nervous System (CNS). The focus of research is on major CNS related conditions, including sleep disorders, Alzheimer's disease, pain management and smoking cessation - fast growing therapeutic areas with large unmet medical needs. Evotec has a diverse product pipeline with candidates at various stages of development. The Company's most advanced product candidate, which has recently completed Phase II clinical trials with excellent results, is EVT 201, a partial positive allosteric modulator of the GABAA receptor complex for the treatment of insomnia. Through selective in-licensing and the use of its platform for internal discovery efforts, Evotec intends to further develop and expand its preclinical and clinical CNS pipeline for partnering.

More about Evotec
  • News

    Evotec and Indivumed announce second joint drug discovery programme

    Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (“NSCLC”). The final goal of this precision medicine collaboration is to deliver highl ... more

    Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome

    Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS). Under the terms of the agreement, both companies ... more

    Evotec and Bristol-Myers Squibb expand iPSC collaboration

    Evotec SE announced that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company following the decision to expand the collaboration to include additional cell lines. Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 201 ... more

  • Companies

    Evotec SE

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE